Modern Diagnostic IPO - AstroIPO

Modern Diagnostic IPO


January 5, 2026 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

Modern Diagnostic & Research Centre Ltd. is set to enter the healthcare sector through its specialized diagnostic services focus. The Modern Diagnostic IPO, running from December 31st, 2025 to January 2nd, 2026, presents a ₹36.89 crore public issue of 40,99,200 shares priced between ₹85 – ₹90 per share.

Market participants can apply for a minimum of 3,200 shares, requiring ₹2,88,000 investment at the upper price band. The Modern Diagnostic IPO shares, carrying ₹10 face value, will debut on BSE, introducing this diagnostic and research centre specialist to the public markets through dedicated healthcare testing sector representation.

Modern Diagnostic IPO Details

The key details of Modern Diagnostic & Research Centre’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.

IPO Size ₹36.89 Cr
Price Range ₹85 - ₹90
Retail Quota 35%
QIB Quota 50%
NII Quota 15%
Employee Discount --
Listing at BSE
Minimum Quantity 3,200
Investment (cut-off price) ₹2,88,000
Pre IPO Promotor Holding 99.99%
Post IPO Promotor Holding 72.85%
DHRP Draft Click Here
RHP Draft Click Here
Anchor Investors List Click Here

Modern Diagnostic IPO Timelines

The IPO process for Modern Diagnostic & Research Centre includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.

31/12/2025
Start Date
02/01/2026
End Date
05/01/2026
Allotment Date View Status
06/01/2026
Refund Initiation
06/01/2026
Credit of Shares to Demat Ac
07/01/2026
Listing Date

Modern Diagnostic IPO Lot Size

The Modern Diagnostic & Research Centre IPO has a fixed lot size of 1,600 shares, at an upper price band of ₹90 per share. For retail investors, the minimum and maximum application is 3,200 shares (2 lots) amounting to ₹2,88,000. For Small HNI (S-HNI) investors, the minimum application is 4,800 shares (3 lots) worth ₹4,32,000, while the maximum is 9,600 shares (6 lots) amounting to ₹8,64,000. Big HNI (B-HNI) investors need to apply for at least 11,200 shares (7 lots), totaling ₹10,08,000.

Application Lot Size Shares Amount
Retail Minimum 2 3200 ₹2,88,000
Retail Maximum 2 3200 ₹2,88,000
S-HNI Minimum 3 4800 ₹4,32,000
S-HNI Maximum 6 9600 ₹8,64,000
B-HNI Minimum 7 11200 ₹10,08,000

Modern Diagnostic IPO Subscription Status

The subscription status for Modern Diagnostic & Research Centre IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.

QIB NII Retail EMP Total
193.51x 702.08x 342.46x -- 376.90x

IPO Performance on Listing Day

Opening Price Closing Price Day High Day Low

Modern Diagnostic IPO Company Financials

Modern Diagnostic & Research Centre reports robust performance in FY2025 with Total Income of ₹78.80 crores, managing expenses at ₹66.08 crores, and achieving a strong PAT (Profit After Tax) of ₹8.97 crores, demonstrating significant growth potential ahead of its public offering.

Year Total Income Total Expense PAT
FY 2023 ₹56.61 ₹62.55 -₹5.73
FY 2024 ₹68.67 ₹61.81 ₹5.79
FY 2025 ₹78.80 ₹66.08 ₹8.97
FY 2026 (3 M) ₹22.67 ₹18.40 ₹3.00

About Company

Incorporated in 1985, Modern Diagnostic & Research Centre Limited (MDRC) is an established diagnostic chain in India offering a comprehensive range of pathology and radiology services. The company provides reliable diagnostic testing, home specimen collection, online report access, and customized test packages tailored to the needs of individual patients as well as institutional clients.

MDRC operates 21 centers across 8 states, including 18 laboratories and 3 diagnostic centers, delivering services such as ultrasound, CT, MRI, X-ray, ECG, PFT, and specialized heart and neuro diagnostics. Its pathology services cover routine testing as well as advanced molecular diagnostics, cytogenetics, and specialized panels for genetic disorders and cancer. The radiology division is equipped with advanced imaging technology, including a 3-Tesla MRI and a 128-slice CT scanner, ensuring high-quality diagnostic accuracy and patient care.

Incorporation Date Sector Managing Director
1985 Healthcare Devendra Singh Yadav

Know Before Investing

When evaluating Modern Diagnostic & Research Centre's IPO potential, understanding both its market advantages and inherent risks becomes crucial for your investment. Below are the key insights you should consider.

Modern Diagnostic IPO Strengths

  • Modern Diagnostic & Research Centre runs a one‑stop diagnostic chain combining pathology, radiology (including 3T MRI, CT, ultrasound), and advanced molecular testing, improving patient convenience and cross‑selling opportunities.
  • Incorporated in 1985 and headquartered in Delhi‑NCR, the company has built long‑standing relationships with patients, hospitals and corporate clients, supporting trust and repeat business.
  • The network spans 21 centres across 8 states, giving regional diversification beyond a single city and scope to leverage centralised processes and systems.
  • Home sample collection, digital report delivery, and centralised IT systems integrating logistics, reporting, and payments enhance patient experience and operational efficiency.
  • Rising healthcare awareness, ageing population, chronic disease burden and increasing insurance penetration are driving steady growth in diagnostics demand across India.

Modern Diagnostic IPO Risks

  • A meaningful share of operations and brand strength is still concentrated in North India (especially Delhi‑NCR and adjoining states), exposing the business to region‑specific competition and regulatory changes.
  • Faces competition from large listed diagnostic chains, hospital‑based labs, and regional standalone centres, which may pressure pricing and market share.
  • The business relies on pathologists, radiologists and technical specialists; attrition or inability to attract talent could impact service quality and patient inflows.
  • Diagnostics is subject to healthcare regulations, quality accreditation requirements, radiation norms and biomedical waste rules; any non‑compliance can result in penalties or reputational damage.
  • Corporate, hospital and B2B clients may have longer credit cycles, increasing working capital needs and risk of delayed collections.

Swot Analysis for Modern Diagnostic IPO

Understanding Modern Diagnostic & Research Centre's SWOT analysis is your first step towards making a confident investment decision. Let's evaluate its core strengths and potential challenges ahead.

Strengths

Integrated Pathology & Radiology Network, Wide Geographic Presence, Long Operating History & Brand Trust

Weaknesses

Operational Disruption Risk, Pathology Revenue Concentration, Technology Upgrade Needs

Opportunities

Rising Diagnostics Demand, Institutional & Corporate Tie-Ups, Digital Health Integration

Threats

Intense Competitive Landscape, Data Privacy & Cyber Risks, Clinical & Legal Risk

Company Details

Modern Diagnostic & Research Centre Ltd.

Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, 110015

Phone: 9999474297

Email: compliance@mdrcindia.com

Website: http://www.mdrcindia.com/

IPO Registar Details

MUFG Intime India Pvt. Ltd.

Phone: +91-22-4918 6270

Email: moderndiagnostic.smeipo@in.mpms.mufg.com

Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html

FAQs

The key objectives of Modern Diagnostic SME IPO are:

  • Funding capital expenditure for purchase of medical Equipments for diagnostic centre and laboratories
  • Funding Working Capital Requirement
  • Repayment of certain outstanding borrowings availed by the Company
  • General Corporate Expenses

Beeline Capital Advisors Pvt. Ltd. is the book-running lead managers for the Modern Diagnostic IPO.

Modern Diagnostic IPO has strong growth potential as lifestyle diseases, insurance coverage, and preventive testing expand the Indian diagnostics market. Its 21 centre network across eight states, advanced radiology and esoteric testing, plus digital booking and home collection support steady volume growth.

The issue price for the Modern Diagnostic IPO is set between ₹85 to ₹90 per share.

To invest in two lot of Modern Diagnostic IPO, you need ₹2,72,000 at the lower price band (₹85 per share) or ₹2,88,000 at the upper price band (₹90 per share) for a lot size of 3200 shares.

Modern Diagnostic IPO shares are scheduled to be listed on the Bombay Stock Exchange (BSE) on January 7, 2025.

Refund/unblocking of funds for Modern Diagnostic IPO will begin on January 6, 2025. ASBA/UPI blocks will be removed within 1 working day.

You can sell shares your Modern Diagnostic IPO shares on listing day (January 7, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.

Leave a Reply

Your email address will not be published. Required fields are marked *